- B.S. Pharmacy, Chung-Ang University, Seoul, South Korea
- M.S. Pharmacy, Chung-Ang University, Seoul, South Korea
- Ph.D. University of Texas at Austin
Pharmacoeconomics and health policy research
Economic and health outcomes evaluation
Haesuk Park, Ph.D., is an Assistant Professor in the Department of Pharmaceutical Outcomes and Policy. She received her Bachelor and Master in Pharmacy from South Korea, and her Ph.D. at The University of Texas at Austin, College of Pharmacy, Health Outcomes & Pharmacy Practice (formerly Pharmacy Administration). For a few years after graduation, she worked at the pharmaceutical company in South Korea. Her research interests lie in economic evaluation and health-related outcome studies of medications and pharmaceutical care services that can potentially improve healthcare services for patients.
Dr. Park has been involved in various outcomes research projects, including cost-effectiveness modeling, budget impact modeling, retrospective database analysis, and meta-analysis. Her dissertation research is titled, “Impact of the Medicare Part D Coverage on Medication Adherence and Health Outcomes in End-Stage Renal Disease (ESRD) Patients.” Her goals related to this research include the effects of the Medicare Part D cost sharing structure on medication adherence, healthcare service utilization and costs, and mortality among patients with ESRD.
Dr. Park is a member of The American Pharmacists Association (APhA) and the International Society for Pharmacoeconomics and Outcomes Research (ISPOR).
Sterling KL, Ford KH, Park H, et al. Assessing the invariance of smoking-related self-efficacy, beliefs, and intention among high school current smokers. Substance Use and Misuse 2013;48(7):477-483.
Sterling KL, Ford KH, Park H, et al. Scales of smoking-related self-efficacy, belief, and intention: assessing measurement invariance among intermittent and daily high school smokers. American Journal of Health Promotion 2013 (in press).
Park H, Park C, Kim YA, Rascati KL. Efficacy and safety of dipeptidyl peptidase-4 [DPP-4] inhibitors in type 2 diabetes: Meta-analysis. Annals Pharmacotherapy 2012;46(11):1453-1469.
Tiwana S, Rascati KL, Park H. Cost-effectiveness of expanded newborn screening in Texas. Value Health, 2012;15(5):613-621.
Park H, Rascati KL, Prasla K, McBayne T. Evaluation of healthcare costs and utilization patterns for patients with gout. Clinical Therapeutics, 2012;34(3):640-652.
Park H, Rascati KL, Keith MS et al. Cost-effectiveness of lanthanum carbonate vs. sevelamer hydrochloride in patients with end-stage renal disease: A US payer perspective. Value Health, 2011;14:1002-1009.
Park H, Rascati KL. Comparing two cost-effectiveness studies of statins for the primary prevention of cardiovascular disease: Are statins cost-effective from a Korean health system perspective? Clinical Therapeutics, 2009;31:2916-2918. [Editorial]
Park H, Yang SW, Choi YW, et al. In vitro skin penetration and pharmacodynamic evaluation of prostaglandin E1 ethyl ester, a vasoactive prodrug of prostaglandin E1, formulated into alcoholic hydrogels, Pharmazie, 2006;61:933-937.